Tvardi Therapeutics
TVRD
70 hedge funds and large institutions have $120M invested in Tvardi Therapeutics in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 32 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
19% more capital invested
Capital invested by funds: $101M → $120M (+$19.4M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
25% less funds holding
Funds holding: 93 → 70 (-23)
66% less call options, than puts
Call options by funds: $26K | Put options by funds: $76K
72% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$3.99M |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
+$2.14M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$808K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$440K |
| 5 |
NPC
National Planning Corporation
El Segundo,
California
|
+$347K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.9M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$7.54M |
| 3 |
Jennison Associates
New York
|
-$4.11M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$866K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$559K |
TVRD Hedge Fund Activity: Q2 2016 in Review
70 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2016, worth a combined $120M — up 19% from $101M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of TVRD and 9 opened new positions — a net loss of 23 holders — while 22 trimmed existing stakes and 28 added.
The largest buyer was Pictet Asset Management (UK), adding an estimated $3.99M. The largest seller was Fidelity Investments, exiting entirely with an estimated $9.9M sold.
- 70 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2016, down from 93 in Q1 2016.
- Funds reported $120M of Tvardi Therapeutics stock for Q2 2016, up 19% quarter-over-quarter.
- 9 funds opened new Tvardi Therapeutics positions in Q2 2016 and 32 closed out, a net change of -23 holders.
- The largest Tvardi Therapeutics buyer in Q2 2016 was Pictet Asset Management (UK), an estimated $3.99M added.
- The largest Tvardi Therapeutics seller in Q2 2016 was Fidelity Investments, an estimated $9.9M sold.
Based on aggregated 13F filings for Q2 2016.